Regencell Bioscience Holdings Limited
RGCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeRegencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. Valued at $2.53B, RGC is a mid-cap name in its sector. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Market Cap
$2.53B
Beta
1.83
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.01
EPS (Fwd)
—
ROE
-177.7%
ROA
-85.0%
Cash
$2.4M
Total Debt
$386,302
Free CF
—
52W Change
-66.5%
Annual Financials
Cash vs Debt
With $2.4M in cash and $386K in debt, RGC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. ROE of -177.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Regencell Bioscience Holdings Limited's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing RGC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.